{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:03Z","timestamp":1758937203653,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.leukres.2019.106286","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T16:41:39Z","timestamp":1575996099000},"page":"106286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"88","author":[{"given":"Hiroaki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Sakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Matsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Koshio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2019.106286_bib0005","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of Non-hodgkin\u2019s lymphoma. The Non-hodgkin\u2019s lymphoma classification project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"6769","key":"10.1016\/j.leukres.2019.106286_bib0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2019.106286_bib0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.106286_bib0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2014.05.002","article-title":"Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms","volume":"14","author":"Read","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2019.106286_bib0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.leukres.2019.106286_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2019.106286_bib0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14712598.2013.786698","article-title":"Rituximab in the treatment of non-Hodgkin\u2019s lymphoma--a critical evaluation of randomized controlled trials","volume":"13","author":"Griffin","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"issue":"12","key":"10.1016\/j.leukres.2019.106286_bib0040","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2019.106286_bib0045","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2019.106286_bib0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"issue":"28","key":"10.1016\/j.leukres.2019.106286_bib0055","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2019.106286_bib0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"43","key":"10.1016\/j.leukres.2019.106286_bib0065","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.1074\/jbc.274.43.30644","article-title":"Syk and Bruton\u2019s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt","volume":"274","author":"Craxton","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.leukres.2019.106286_bib0070","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","article-title":"Bruton\u2019s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement","volume":"191","author":"Petro","year":"2000","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.leukres.2019.106286_bib0075","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nri953","article-title":"Lymphoid malignancies: the dark side of B-cell differentiation","volume":"2","author":"Shaffer","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.leukres.2019.106286_bib0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2019.106286_bib0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2019.106286_bib0090","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 mutations and response to Ibrutinib in Waldenstrom\u2019s macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2019.106286_bib0095","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.leukres.2019.106286_bib0100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-17-1033","article-title":"Pharmacological and structural characterizations of Naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer","volume":"17","author":"Hirano","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.leukres.2019.106286_bib0105","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1535-7163.MCT-18-0976","article-title":"Mutant-selective irreversible EGFR inhibitor, Naquotinib, inhibits tumor growth in NSCLC models with EGFR-Activating mutations, T790M mutation, and AXL overexpression","volume":"18","author":"Tanaka","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.leukres.2019.106286_bib0110","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1158\/1078-0432.CCR-17-1447","article-title":"Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations","volume":"23","author":"Yu","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7276","key":"10.1016\/j.leukres.2019.106286_bib0115","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.leukres.2019.106286_bib0120","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1016\/j.bmcl.2008.07.062","article-title":"Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase","volume":"18","author":"Hur","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.leukres.2019.106286_bib0125","article-title":"Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma, submitted to molecular cancer therapeutics","author":"Tanaka","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"7277","key":"10.1016\/j.leukres.2019.106286_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.leukres.2019.106286_bib0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040127","article-title":"Responses to the selective Bruton\u2019s tyrosine kinase (BTK) inhibitor tirabrutinib (ONO\/GS-4059) in diffuse large B-cell lymphoma cell lines","volume":"10","author":"Kozaki","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.leukres.2019.106286_bib0140","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jps.23452","article-title":"Correlation of tissue-plasma partition coefficients between normal tissues and subcutaneous xenografts of human tumor cell lines in mouse as a prediction tool of drug penetration in tumors","volume":"102","author":"Poulin","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.leukres.2019.106286_bib0145","first-page":"4396","article-title":"Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids","volume":"6","author":"Yoshida","year":"2000","journal-title":"Clin. Cancer Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:12Z","timestamp":1758934812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619307313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"alternative-id":["S0145212619307313"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106286","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106286"}}